Market Place

Market Place

Market Place

Menu

Post Enquiry

Post Enquiry

PharmaCompass

Home

Market Place

Market Place

Search
All
API
FDF
Price
Services
Excipients
Enquiries

    Find

    • Active Pharmaceutical Ingredients Active Pharmaceutical Ingredients
    • Finished Drug Formulations Finished Drug Formulations
    • Price Price
    • Excipients Excipients
    • Services Services
    • Market Place Marketplace

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    pipeline-prospector-insert
    X

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Loading...

    All Data

    Filters Filter refresh
    ×
    FILTER DATA :
    News Type filter
      Company filter
        Product Type filter
          Deal Size filter
            Upfront Payment filter
              refresh

              Product Type Full Screen

              Companies Full Screen

              Horizon Therapeutics

              • Development Update

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              IRELAND Ireland

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              IFT Annual Expo

              Participation Not Confirmed

              Update your events

              Data Presented on KRYSTEXXA Co-Prescribed with an Immunomodulator Adds to Growing Body of Evidence for this Treatment Approach

              Contact the Supplier

              Lead Product(s): Pegloticase

              Therapeutic Area: Musculoskeletal Product Name: Undisclosed

              Highest Development Status: Phase IV Product Type: Large molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable June 03, 2020

              Details:

              Data presentations demonstrate that KRYSTEXXA® (pegloticase injection) can be co-prescribed with three commonly used immunomodulators in rheumatology to potentially help more people with chronic gout refractory to conventional therapies.

              Horizon Therapeutics

              • Development Update

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              IRELAND Ireland

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              IFT Annual Expo

              Participation Not Confirmed

              Update your events

              Horizon Therapeutics To Present Data on Multiple Immunomodulation Approaches with KRYSTEXXA at the EULAR 2020

              Contact the Supplier

              Lead Product(s): Pegloticase

              Therapeutic Area: Musculoskeletal Product Name: Undisclosed

              Highest Development Status: Phase IV Product Type: Large molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable May 21, 2020

              Details:

              Presentations of trial data and in-practice cases will provide results on KRYSTEXXA® (pegloticase injection) with commonly used immunomodulators to help more people with chronic gout refractory to conventional therapies potentially achieve complete response to treatment.

              PharmaCompass__DigitalAd